Topical Finasteride Is Safer Than Oral, But the Pharmacokinetic Data Tells a More Complicated Story

Compounded topical finasteride has become one of the most commonly prescribed off-label hair loss treatments in dermatology, largely on the strength of a Phase 3 trial (Almirall's P-3074) that showed comparable efficacy to oral finasteride 1mg with reduced serum DHT suppression. The trial reported scalp DHT reductions of 56% versus 73% for oral, meaningful local effect with substantially less systemic exposure. For patients who fear sexual side effects, that's a compelling tradeoff.

The pharmacokinetic detail that gets less attention: topical finasteride does absorb systemically, just less than oral. Serum finasteride concentrations in the P-3074 trial were approximately 25% of those achieved with the oral 1mg dose. Serum DHT suppression averaged 35% versus 71% for oral. That 35% suppression is not zero, it's still a meaningful systemic effect, and it's not realistic to assume topical formulation completely eliminates the risk of androgenic side effects.

What the topical version does change is the dose-response curve. At equivalent scalp DHT reduction, systemic exposure is substantially lower than oral. For patients who experienced significant sexual side effects on oral finasteride, switching to a properly formulated topical may reduce, though not eliminate, those effects. Patients who are highly sensitive to androgen suppression should be cautious; topical doesn't make finasteride into placebo. Patient selection and honest informed consent matter as much as formulation choice.